Jason Amello's Net Worth

$2.54 Million

Estimate Recalculated Mar 20, 2025 08:36PM EST

Who is Jason Amello

Jason Amello has an estimated net worth of $2.54 Million. This is based on reported shares across multiple companies, which include TScan Therapeutics, Inc., GENZYME CORP, ZIOPHARM ONCOLOGY INC, Akebia Therapeutics, Inc., Acer Therapeutics Inc., and Candel Therapeutics, Inc..

SEC CIK

Jason Amello's CIK is 0001451805

Past Insider Trading and Trends

2022 was Jason Amello's most active year for acquiring shares with 5 total transactions. Jason Amello's most active month to acquire stocks was the month of January. 2011 was Jason Amello's most active year for disposing of shares, totalling 13 transactions. Jason Amello's most active month to dispose stocks was the month of March. 2017 saw Jason Amello paying a total of $481,650.00 for 86,500 shares, this is the most they've acquired in one year. In 2011 Jason Amello cashed out on 65,364 shares for a total of $3,512,819.70, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

TScan Therapeutics, Inc.

Chief Financial Officer
Updated Feb 02, 2024
Form 4
750.00K
Feb 02, 2024
750.00K
Grant
Feb 01
Form 3
Feb 02, 2024
Showing 2 results

GENZYME CORP

CorpContrllr,ChiefAccntOfficer
Updated Apr 06, 2011
Form 4
-100.00%
-60.36K
$65.41
-$3.51M
Apr 06, 2011
Options
Apr 04
Form 4
-67.00%
-6.64K
$52.26
-$466.79K
Sep 02, 2010
3.27K
Sale
Aug 31
Form 4
5.79K
$51.52
$223.60K
Jun 18, 2010
5.79K
Grant
Jun 16
Form 4
-6.55%
-533.00
$45.62
-$24.32K
May 26, 2010
7.61K
Sale
May 24 - May 25
Form 4
7.27K
May 26, 2009
7.27K
Grant
May 21
Form 3/A
Jan 06, 2009
1.43K
Form 3
Dec 10, 2008
1.43K
Showing 7 results

ZIOPHARM ONCOLOGY INC

Executive Vice President & CFO
Updated May 14, 2013
Form 4
-10.49%
-2.62K
$1.65
-$4.33K
May 14, 2013
22.38K
Tax
May 08
Form 4
150.00K
Jan 03, 2013
150.00K
Grant
Dec 31
Form 4
200.00K
Jun 22, 2012
200.00K
Grant
Jun 20
Form 4
25.00K
May 10, 2012
25.00K
Grant
May 08
Form 3
May 10, 2012
Showing 5 results

Akebia Therapeutics, Inc.

SVP, CFO & Treasurer
Updated Mar 02, 2020
Form 4
55.93%
68.02K
$8.70
-$60.69K
Mar 02, 2020
189.64K
Grant
Feb 28
Form 4
-9.98%
-13.15K
$7.70
-$101.24K
Apr 12, 2019
118.62K
Disposition
Apr 11
Form 4
247.13%
165.00K
Mar 05, 2019
231.77K
Grant
Feb 28
Form 4
-25.06%
-22.23K
$8.94
-$198.78K
Dec 13, 2018
66.50K
Tax
Dec 12
Form 4
69.68%
47.20K
Mar 02, 2018
114.94K
Grant
Feb 28
Form 4
217.47%
77.50K
$10.14
$481.65K
Feb 23, 2017
113.14K
Grant
Feb 21
Form 4
895.63%
65.65K
Feb 24, 2016
72.98K
Grant
Feb 22
Form 4
45.00K
Mar 10, 2015
45.00K
Grant
Mar 06
Form 4
25.00%
1.00K
$13.22
$13.22K
Dec 01, 2014
5.00K
Purchase
Nov 26
Form 4
21.67K
Aug 05, 2014
21.67K
Grant
May 14
Form 4
4.00K
$17.00
$68.00K
Mar 27, 2014
4.00K
Purchase
Mar 25
Form 3
Mar 19, 2014
Showing 12 results

Acer Therapeutics Inc.

Investor
Updated Mar 16, 2023
Form 4
20.00K
Mar 16, 2023
20.00K
Grant
Mar 14
Form 4
18.50K
Jan 19, 2022
18.50K
Grant
Jan 14
Form 4
15.00K
Jan 20, 2021
15.00K
Grant
Jan 15
Form 4
9.00K
Jan 03, 2020
9.00K
Grant
Jan 02
Form 4
6.00K
Feb 05, 2019
6.00K
Grant
Feb 01
Form 4
9.00K
Oct 06, 2017
9.00K
Grant
Oct 04
Form 3
Sep 21, 2017
Showing 7 results

Candel Therapeutics, Inc.

Chief Financial Officer
Updated Nov 30, 2023
Form 4
-9.07%
-20.15K
$0.90
-$18.14K
Nov 30, 2023
202.01K
Tax
Nov 28
Form 4
130.35%
125.72K
Nov 28, 2023
222.16K
Grant
Nov 26
Form 4
90.00K
May 02, 2023
90.00K
Grant
Apr 28
Form 4
5.57K
$1.80
$10.00K
Dec 12, 2022
5.57K
Purchase
Dec 08 - Dec 09
Form 4
90.88K
Nov 30, 2022
90.88K
Grant
Nov 28
Form 4
230.00K
Sep 23, 2022
230.00K
Grant
Sep 21
Form 3
Sep 23, 2022
Showing 7 results